ASSOCIATION OF «TRADITIONAL» RISK FACTORS AND CHEMOCIN CXCL16 LEVEL IN THE DEVELOPMENT OF CARDIOVASCULAR EVENTS

Material and methods. We analyzed the results of the observation of 223 persons aged 25 to 65 years (177 women, 46 men) from May 2014 to December 2018. The study included socio-demographic, anthropometric data, blood pressure measurement, the study of cholesterol, glucose, chemokine CXCL16. For the cardiovascular event took the development of acute cerebrovascular accident, acute coronary syndrome, transient ischemic attack, first diagnosed angina. Data analysis was performed using the SPSS 22 statistical software package. Results and discussion. The frequency of cardiovascular events was 15.7%. Differences were found between groups depending on age (p=0.002), systolic blood pressure level (p=0.029), waist size (p=0.003), risk degree on a SCORE scale (р=0,002), and CXCL16 chemokine level (p=0.009). Conclusion. The relationship between the SCORE scale, the CXCL 16 chemokine level and the development of cardiovascular events has been found. Findings. Further research is needed on the prognostic evaluation of biomarkers.

SCORE scale, cardiovascular events, chemokine CXCL16, SCORE шкаласы

1. Искаков Е. Б. Эпидемиология сердечно-сосудистых заболеваний //Медицина и экология. - 2017. - №1. - С. 19-28.

2. Кочергина А. М. Гендерные различия факторов кардиоваскулярного риска у пациентов разных возрастных групп (по данным исследования ЭССЕ-РФ) /А. М. Кочергина, В. Н. Каретникова, О. Л. Барбарам //Медицина в Кузбасе. - 2015. - №1. - С. 1-8.

3. Приказ МЗ РК № 669 от 31 августа 2017 года «О внесении изменения в Приказ Министра здравоохранения Республики Казахстан от 9 сентября 2010 года №704 «Об утверждении Правил организации скрининга»

4. Degano I. The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index /i. R. Degano, J. Marrugat, M. Grau // Scientific Reports. - 2017. - №7 (1). - P. 1-8.

5. Dhingra R. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework /R. Dhingra, R. Vasan //Clinical and pharmacological therapy. - 2001. - V. 69. - P. 89 -95.

6. Dhingra R. Biomarkers in Cardiovascular Disease. Statistical Assessment and Section on Key Novel Heart Failure Biomarkers /R. Dhingra, R. Vasan //Trends Cardiovascular Medicine. -2017. - V. 27(2). - P. 123-133.

7. Fan H. Abdominal obesity is strongly associated with cardiovascular disease and its risk factors in elderly and very elderly communitydwelling Chinese /H. Fan, X. Zheng, X. Chen // Sci. Rep. - 2016. - V. 6: 21521.

8. Galiuto L. Gender differences in cardiovascular disease /L. Galiuto, G. Locorotondo // Journal of Integrative Cardiology. - 2015. - V. 1 (1). - P. 20-22.

9. Huang Y. Biomarkers of cardiovascular disease /Y. Huang, K. Gulshan, T. Nguyen, Y. Wu //Disease Markers. - 2017. - V. 24. - P. 1-2.

10. Laugsand L. E. Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway /l. E. Laugsand, B. O. Asvold, L. J. Vatten // Atherosclerosis. - 2016. - V. 244. - P. 188-194.

11. Lehrke M. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans /M. Lehrke, S. C. Millington, M. Lefterova //J. Am. Coll. Cardiol. - 2007. - V. 49 (4). - P. 442-449.

12. National Center for Health Statistics (NCHS) and the National Heart, Lung, and Blood Institute (NHLBI), Women and Cardiovascular Diseases - Statistics, 2009.

13. Nazari A. Cardiovascular Disease in Iranian Hemodialysis Patients /A. Nazari, A. M. Sardoo, E. T. Fard //biomedical and pharmacology journal. - 2017. - V. 10 (1). - P. 1-7.

14. Oguoma V. M. Prevalence of cardiovascular disease risk factors among a Nigerian adult population: relationship with income level and accessibility to CVD risks screening /V. M. Oguoma, E. U. Nwose, T. C. Skinner //BMC Public Health. - 2015. - V. 15. - P. 397.

15. Piepoli M. F. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The 6th Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) /M. F. Piepoli, A. W. Hoes, S. Agewall // European Heart Journal. - 2016. - V. 37 (29). - P. 2315-2381.

16. Shields M. Abdominal obesity and cardiovascular disease risk factors within body mass index categories /M. Shields, M. S. Tremblay, S. Connor Gorber //Health Rep. - 2012. - V. 23 (2). - P. 7-15.

17. Simon-Tuval T. The association between adherence to cardiovascular medications and healthcare utilization /T. Simon-Tuval, N. Triki, G. Chodick //The European Journal of Health Economics. - 2008. - V. 17 (5). - P. 603-610.

18. Thomas L. Lower Education Level Is Associated with Higher Risk for Cardiovascular Disease /L. Thomas, Y. Kubota //NEJM Journal Watch. - 2017. - V. 1 (3). - P. 1-2.

19. Tohoku J. CXC chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: a 2-year follow-up study //Experimental Medicine. - 2011. - V. 223 (4). - P. 277-283.

20. Wang J. Novel biomarkers for cardiovascular risk prediction /J. Wang, G. J. Tan, L. N. Han //Journal of Geriatric Cardiology. - 2017. -V.14(2). - P. 135-150.

21. Wong C. W. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis /C. W. Wong, C. S. Kwok, A. Narain //Heart. - 2018. - V. 104 (23). - P. 19371948.